Clofazimine pKa Determination by Potentiometry and Spectrophotometry: Reverse Cosolvent Dependence as an Indicator of the Presence of Dimers in Aqueous Solutions.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.3c00172
Abstract: The weakly basic antibiotic and anti-inflammatory drug, clofazimine (CFZ), was first described in 1957. It has been used therapeutically, most notably in the treatment of leprosy. However, the compound is extremely insoluble in aqueous media,… read more here.
Keywords: cfz; cosolvent dependence; pka; reverse cosolvent ... See more keywords
Facile Strategy Enabling Both High Loading and High Release Amounts of the Water-Insoluble Drug Clofazimine Using Mesoporous Silica Nanoparticles.
Sign Up to like & getrecommendations! Published in 2018 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.8b09069
Abstract: The use of nanocarriers to deliver poorly soluble drugs to the sites of diseases is an attractive and general method, and mesoporous silica nanoparticles (MSNs) are increasingly being used as carriers. However, both loading a… read more here.
Keywords: cfz; msns; water insoluble; drug ... See more keywords
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01141-4
Abstract: Carfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma but is associated with cardiovascular adverse events (CVAEs). We prospectively investigated the effect of CFZ on endothelial function and associations with CVAEs. Forty-eight patients treated with Kd… read more here.
Keywords: cfz; recovery; fmd; proteasome activity ... See more keywords
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-17596-4
Abstract: Proteasome inhibitors, e.g. Bortezomib (BTZ) and Carfilzomib (CFZ), have demonstrated clinical efficacy against haematological cancers. Interestingly, several adverse effects are less common, compared to BTZ, in patients treated with CFZ. As the molecular details of… read more here.
Keywords: cfz; drosophila; degenerative effects; cfz btz ... See more keywords
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-40635-1
Abstract: The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life. A considerable portion of patients however display intrinsic resistance… read more here.
Keywords: cfz; h727 cells; proteasome inhibitor; inhibitor carfilzomib ... See more keywords
Olive oil and flaxseed oil incorporating niosomes for enhanced in vivo anti-diabetic efficacy of canagliflozin
Sign Up to like & getrecommendations! Published in 2024 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2024.2409167
Abstract: Abstract Background Canagliflozin (CFZ) is broadly implicated for the management of type 2 diabetes mellitus. Unfortunately, it has low oral bioavailability due to poor solubility behavior and restricted membrane permeability. Objective The current work focuses… read more here.
Keywords: niosomes enhanced; anti diabetic; drug; cfz ... See more keywords
Development and optimization of amphiphilic self-assembly into nanostructured liquid crystals for transdermal delivery of an antidiabetic SGLT2 inhibitor
Sign Up to like & getrecommendations! Published in 2022 at "Drug Delivery"
DOI: 10.1080/10717544.2022.2144546
Abstract: Abstract The anti-hyperglycemic sodium glucose co-transporter 2 inhibitor Canagliflozin (CFZ) represents a recent antihyperglycemic modality, yet it suffers from low oral bioavailability. The current work aims to formulate CFZ-loaded transdermal nanostructured liquid crystal gel matrix… read more here.
Keywords: cfz; inhibitor; delivery; cfz nlcg2 ... See more keywords
Cancer targeting carfilzomib nanomedicine: a comprehensive review of delivery vehicles and efficacy.
Sign Up to like & getrecommendations! Published in 2025 at "Nanomedicine"
DOI: 10.1080/17435889.2025.2579621
Abstract: ABSTRACT Cancer therapy is an ever-changing landscape in constant demand of innovative approaches. Carfilzomib (CFZ) is a tetrapeptide epoxyketone covalent proteasome inhibitor currently approved for the treatment of refractory multiple myeloma. CFZ has a litany… read more here.
Keywords: cancer; review; delivery; cfz ... See more keywords
Clinical Outcomes of Clofazimine Use for Rapidly Growing Mycobacterial Infections
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz456
Abstract: Rapidly growing mycobacteria (RGM) have high rates of intrinsic antibiotic resistance and require prolonged antibiotic therapies associated with considerable toxicity. Less toxic and more effective therapies are needed. One promising agent is clofazimine (CFZ), an… read more here.
Keywords: cfz; clinical outcomes; treatment; infection ... See more keywords
Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis
Sign Up to like & getrecommendations! Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00324-17
Abstract: ABSTRACT Certain Staphylococcus aureus strains exhibit an inoculum effect (InE) with cefazolin (CFZ) that has been associated with therapeutic failures in high-inoculum infections. We assessed the in vitro activities of ceftaroline (CPT), CFZ, and nafcillin… read more here.
Keywords: cfz; staphylococcus aureus; cpt; inoculum effect ... See more keywords
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00441-22
Abstract: Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated.… read more here.
Keywords: adverse effects; cfz; cfz serum; serum concentration ... See more keywords